Beam Therapeutics (MEX:BEAM) ROCE %: -30.76% (As of Mar. 2026)


MEX:BEAM Beam Therapeutics Inc MEX:BEAM
68 GF Score
Price MXN628.46
GF Value MXN541.64
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is Beam Therapeutics ROCE %?

Beam Therapeutics MEX:BEAM 68 ROCE % is -30.76% as of Mar. 2026. GuruFocus rates MEX:BEAM with a GF Score™ of 68/100 and a GF Value™ of MXN541.64 (Modestly Overvalued). The stock has 6 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Beam Therapeutics's annualized ROCE % for the quarter that ended in Mar. 2026 was -30.76%.

Beam Therapeutics  (MEX:BEAM) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Beam Therapeutics ROCE % Related Terms

Beam Therapeutics ROCE % Historical Data

* Premium members only.

The historical data trend for Beam Therapeutics's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Beam Therapeutics ROCE % Chart

Beam Therapeutics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only -49.07 -27.69 -13.91 -42.79 -31.30

Beam Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -42.13 -36.18 -42.67 -5.51 -30.76
MEX:BEAM
68GF Score
Beam Therapeutics Inc MEX:BEAM
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Beam Therapeutics ROCE % Calculation

Beam Therapeutics's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-6908.661/( ( (23021.022 - 3797.114) + (26669.629 - 1745.383) )/ 2 )
=-6908.661/( (19223.908+24924.246)/ 2 )
=-6908.661/22074.077
=-31.30 %

Beam Therapeutics's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=-7733.504/( ( (26669.629 - 1745.383) + (26702.786 - 1344.608) )/ 2 )
=-7733.504/( ( 24924.246 + 25358.178 )/ 2 )
=-7733.504/25141.212
=-30.76 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -30.76% mean?
Beam Therapeutics (MEX:BEAM) has a ROCE % of -30.76% as of Mar. 2026.
Is Beam Therapeutics' ROCE % too high?
Beam Therapeutics' current ROCE % is -30.76%. Overall, Beam Therapeutics has a GF Score™ of 68/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Beam Therapeutics' ROCE % compare to DNLI and ORKA?
Beam Therapeutics' ROCE % of -30.76% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Beam Therapeutics's current ROCE % is -30.76%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beam Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Beam Therapeutics (MEX:BEAM) is currently considered Modestly Overvalued. The stock's GF Value™ is MXN541.64, compared to a current price of MXN628.46 — trading 16% above its estimated fair value. The current ROCE % is -30.76%. Beam Therapeutics' overall GF Score™ is 68/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Beam Therapeutics (MEX:BEAM), the current ROCE % is -30.76% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Beam Therapeutics (MEX:BEAM) Overvalued in 2026?

Based on GuruFocus' analysis, Beam Therapeutics stock appears to be overvalued. The current stock price of MXN628.46 is trading 16% above its estimated GF Value™ of MXN541.64. GuruFocus considers Beam Therapeutics to be Modestly Overvalued.

Key valuation signals for MEX:BEAM:

  • ROCE %: -30.76%
  • GF Value™: MXN541.64 vs. price of MXN628.46 (16% above fair value)
  • GF Score™: 68/100 with 6 warning signs

No single metric tells the full story. See the MEX:BEAM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Beam Therapeutics Business Description

Other Exchanges BEAM:USA
Address 238 Main Street, Cambridge, MA, USA, 02142
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.
68GF Score

Get the complete analysis for MEX:BEAM

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN628.46
Price
MXN541.64
GF Value